Table 3.
Studies Describing Burkholderia cepacia Complex Bloodstream Infections in Patients Without Cystic Fibrosis
| Characteristics | This Study | Liao et al [27] | Bressler et al [25], Woods et al [26] | Lu et al [12] | Huang et al [13] |
|---|---|---|---|---|---|
| Study population | |||||
| Time frame | 1999–2015 | 2004–2007 | 1996–2002 | 1982–1995 | 1997–1999 |
| No. of cases | 248 | 95 | 53, 9 with cystic fibrosis | 70 | 42 |
| Age, y, mean (range) | 68 (22–94) | 69 (55–87) | 46 (24–82) | 34 (median, <1–83) | 70 (2–92) |
| Source | |||||
| Catheter-related infection | 155/248 (63) | 21/95 (22) | … | 11/70 (16) | 8/42 (19) |
| Respiratory tract infection | 49/248 (20) | 47/95 (49) | … | 17/70 (24) | 20/42 (48) |
| Nosocomial | 225/248 (91) | All cases | All cases | 64/70 (91) | 40/42 (95) |
| Susceptibility pattern | |||||
| Trimethoprim-sulfamethoxazole | 193/205 (89) | 0/73 (0) | 44/53 (83) | … | 36/42 (86) |
| Ceftazidime | 152/212 (72) | 71/73 (97) | 37/40 (92) | 41/43 (95) | 40/42 (95) |
| Meropenem | 22/32 (69) | 73/73 (100) | … | … | … |
| Imipenem | 54/136 (40) | … | 5/40 (13) | 23/38 (61) | 32/42 (76) |
| Recorded outcomes | |||||
| 14-d mortality | 40/248 (16) | 16/95 (17) | 25/53 (47) | 8/70 (11) | … |
| 30-d mortality | 61/248 (25) | … | … | … | … |
| In-hospital mortality | … | 51/95 (54) | … | … | 27/42 (64) |
Data are presented as No. (%) unless otherwise indicated.